분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-12-22 19:18:04 , Hit : 511
 FDA Approves First Gene Therapy for Inherited Disease

https://www.genengnews.com/gen-news-highlights/fda-approves-first-gene-therapy-for-inherited-disease/81255291/?utm_medium=newsletter&utm_source=gen+daily+news+highlights&utm_content=01&utm_campaign=gen+daily+news+highlights_20171220

December 20, 2017


FDA approved Spark Therapeutics’ gene therapy Luxturna™   (voretigene neparvovec-rzyl) for treating children and adults with the rare inherited blindness disorder biallelic RPE65 mutation-associated retinal dystrophy. Approval of the one-time adeno-associated virus vector (AAV)-delivered gene therapy, which FDA Commissioner Scott Gottlieb, M.D., described in a statement as “a milestone that reinforces the potential of this breakthrough approach in treating a wide-range of challenging disease,” marks the first gene therapy approval for a genetic disease. Spark has not confirmed the cost of treatment, although some commentators are anticipating a $1 million per patient price tag. Luxturna is currently under review by the European Medicines Agency.

FDA clearance of Luxturna marks the third approval by the agency for a gene therapy, but the first for an AAV-based treatment. In August this year, the U.S. regulator cleared Novartis’ cell-based chimeric antigen receptor T-cell (CAR-T) gene therapy Kymriah™  (tisagenlecleucel) for treating refractory or relapsed B-cell acute lymphoblastic leukemia. In October, Kite Pharma’s CAR-T therapy Yescarta™ (axicabtagene ciloleucel)  was given the FDA nod for treating refractory or relapsed diffuse large B-cell lymphoma.

Administered as a subretinal injection, Luxturna uses an AAV vector to deliver a normal copy of the RPE65 gene to viable retinal cells in patients with confirmed disease. The gene therapy has been tested in two open-label Phase I studies and one open-label, controlled Phase III study, involving 41 participants aged four to 44 years at the time of treatment.

Luxturna will be administered to patients with genetically confirmed disease, by specially trained surgeons at selected centers in the U.S. Spark anticipates that the gene therapy will be available during the first quarter of 2018. The firm will manufacture Luxturna at its facility in West Philadelphia, which it says is the first manufacturing facility in the U.S. licensed for a gene therapy to treat an inherited disease.

“During the more than 12 years of innovative research with dedicated collaborators near and far, I’ve witnessed the dramatic improvement in vision in many patients who would have otherwise lost their sight,” commented Jean Bennett, M.D. Ph.D., the F.M. Kirby Professor of Ophthalmology in the Perelman School of Medicine at the University of Pennsylvania and Penn’s Scheie Eye Institute. “I believe that the success of the Luxturna clinical development program will pave the way for the development of other gene therapies that may help the millions of patients with genetic diseases who currently have limited or no treatment options.”

“This approval is a watershed milestone,” added Benjamin Yerxa, Ph.D., CEO at the Foundation Fighting Blindness (FFB), a nonprofit organization focused on research for preventing and treating blindness caused by inherited retinal diseases. “For people with an inherited retinal disease and for other patient communities, this decision may create important momentum for investigational gene therapies."

  








1107   Dynamic view of the MS genome  이성욱 2010/05/01 2717
1106   Early-Earth cells modeled to show how first life forms might have packaged RNA  이성욱 2012/10/16 2515
1105   Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 820
1104   Efficient Process Using microRNA Converts Human Skin Cells Into Neurons  이성욱 2011/07/19 2238
1103   Electronics Giant Samsung Makes First Big Biotech Play  이성욱 2013/02/22 3165
1102   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1282
1101   Embryonic stem cells improve vision for two women  이성욱 2012/01/25 2336
1100   Engineered Human Liver Tissue Grows in Mice  이성욱 2017/07/25 780
1099   Engineered Viruses Selectively Kill Cancer Cells  이성욱 2011/09/02 2444
1098   Engineering Better Immune Cells  이성욱 2010/05/06 2699
1097   EU, 2번째 유전자치료제 ‘스트림벨리스’ 승인  이성욱 2016/09/05 1146
1096   European regulators back first gene therapy drug  이성욱 2012/07/24 2669
1095   Exosomes Linked to Cancer Spread from Chemoresistant Tumors in Mice  이성욱 2019/01/15 778
1094   Expanding the reach of gene editing with a new CRISPR enzyme  이성욱 2018/10/26 399
1093   Experimental Hepatitis C Drug Shows Promise for Preventing Recurrence in Liver Transplant Patients  이성욱 2013/11/06 2134
1092   Experts find rogue stem cells in liver cancer  이성욱 2011/07/09 2570
1091   Fathers Can Pass Mitochondrial DNA to Children  이성욱 2018/12/26 793
1090   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1142
  FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 511
1088   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 608

[1][2][3][4][5][6][7][8] 9 [10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN